Hong Shen

This inventor holds 43 USPTO granted patents and 34 published patent applications, plus 1 CIPO patent and 30 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Hoffmann-La Roche Inc., Merck Sharp + Dohme Corp., Chinese Academy of Sciences. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hong Shen. Retrieved from https://idiyas.com/inventor/hong-shen-3egja2bo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 43 (Patent Applications = 34)

% Patents Active = 81.4

CIPO Patents = 1 (Patent Applications = 23)

EPO Patents = 30 (Patent Applications = 60)

Average Co-Inventor Count = 6.8

ph-index = 6

Forward Citations = 109(Granted Patents)

Location History:

West Windsor, NJ (US) (2012 - 2016)
Pudong, CN (2015 - 2016)
Shanghai, CN (2010 - 2024)

Company Filing History:

27 out of 5,026

Hoffmann-La Roche Inc.

patents

10 out of 2,405

Merck Sharp + Dohme Corp.

patents

4 out of 3,363

Chinese Academy of Sciences

Shanghai Zhenchun Cosmetics Co., Ltd.

patent

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Triazatricycle Compounds

Heteroaryldihydropyrimidines

Pyrazolopyridine Compounds

Cyclic Amidine Compounds

Peptide Macrocycles

Mineralocorticoid Receptor Antagonists

Ferroelectric Materials

Quantum Dots

Heterojunction Detectors

Combination Therapy

Xanthone Derivatives

Infectious Diseases

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12503471 - Triazatricycle compounds for the treatment of autoimmune disease (2025-12-23),

2. 12357075 - Cosmetics container (2025-07-15),

3. 12351575 - 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection (2025-07-08),

4. 12252484 - Pyrazolopyridine compounds for the treatment of autoimmune disease (2025-03-18),

5. 12247036 - Tricyclic compounds for the treatment of cancer (2025-03-11),

6. 12157746 - Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease (2024-12-03),

7. 12012466 - Peptide macrocycles against (2024-06-18),

8. 12012390 - Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease (2024-06-18),

9. 11999888 - Method for in-situ modification of mercury quantum dots in traditional thermal injection process (2024-06-04),

10. 11784265 - Mercury cadmium telluride-black phosphorous van der waals heterojunction infrared polarization detector and preparation method thereof (2023-10-10),

11. 11713327 - Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease (2023-08-01),

12. 11548884 - Cyclic amidine compounds for the treatment of autoimmune disease (2023-01-10),

13. 11168086 - Methods of synthesizing pyrazine compounds (2021-11-09),

14. 11100971 - Ferroelectric domain regulated optical readout mode memory and preparing method thereof (2021-08-24),

15. 11098080 - Peptide macrocycles against Acinetobacter baumannii (2021-08-24),

Title: An Overview of Hong Shen’s Innovative Contributions in Patent Development

Introduction

Hong Shen, based in Shanghai, China, is an accomplished inventor with an impressive portfolio of 38 patents. His work primarily focuses on novel compounds that address significant medical challenges, particularly in the field of autoimmune diseases. With a solid background in pharmaceutical research, Hong Shen has made notable strides in innovation.

Latest Patents

Among his latest contributions are groundbreaking patents involving Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds designed for the treatment of autoimmune diseases. The invention outlines compounds of specific formulas, detailing various acceptable salts, enantiomers, and diastereomers, along with methods for their use. In addition, he has developed peptide macrocycles that hold promise against various medical conditions, further illustrating his innovation in pharmaceutical compounds.

Career Highlights

Hong Shen has worked with prominent pharmaceutical companies, including Hoffmann-La Roche Inc. and Merck Sharp & Dohme Corporation. His role in these organizations showcases his commitment to advancing medical research and enhancing therapeutic options through innovative discoveries.

Collaborations

Throughout his career, Hong Shen has collaborated with talented individuals such as Taishan Hu and Zhisen Zhang. These partnerships have facilitated knowledge exchange and spurred the development of new ideas, reinforcing the essence of teamwork in the realm of scientific innovation.

Conclusion

In summary, Hong Shen stands out as a significant contributor to the field of invention and patent development. His commitment to innovation and collaboration continues to drive advancements in medical research, undoubtedly paving the way for future solutions to complex health issues.

Profile summary based on public USPTO records.